Vivesto
Vivesto AB, formerly Oasmia Pharmaceutical, is a Swedish clinical-stage pharmaceutical enterprise developing targeted drug formulations for hard-to-treat cancers. The company utilizes its proprietary XR-17 and Apealea drug delivery platforms to enhance the solubility and bioavailability of active pharmaceutical ingredients. Revenue is primarily generated through research collaboration upfront fees, clinical milestone payments, and commercial distribution licensing contracts with biopharmaceutical partners. Core end markets serve oncology practices, clinical hospitals, and cancer research centers in Europe and international markets. Vivesto holds a specialized position in the European biopharmaceutical sector as a developer of proprietary drug formulation technologies for oncology. The company is headquartered in Solna, Sweden, and its ordinary shares trade on the Nasdaq Stockholm exchange.
2 of the funds FundTelligence covers report a position in Vivesto.
- Legal name
- Vivesto AB
- Sector
- Health Care
- Country
- Sweden
- Funds holding it
- 2
Funds holding Vivesto
- Storebrand Sverige Småbolag Plus — Storebrand · 0.0 % (full portfolio disclosed, October 2026)
- Storebrand Sverige Plus — Storebrand · 0.0 % (full portfolio disclosed, October 2026)